Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.

Korniejewska A, McKnight AJ, Johnson Z, Watson ML, Ward SG.

Immunology. 2011 Apr;132(4):503-15. doi: 10.1111/j.1365-2567.2010.03384.x. Epub 2011 Jan 24.

2.

Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.

Watts AO, Scholten DJ, Heitman LH, Vischer HF, Leurs R.

Biochem Biophys Res Commun. 2012 Mar 9;419(2):412-8. doi: 10.1016/j.bbrc.2012.02.036. Epub 2012 Feb 13.

PMID:
22349504
3.

Analysis of CXCR3 and atypical variant expression and signalling in human T lymphocytes.

Korniejewska A, Watson M, Ward S.

Methods Mol Biol. 2010;616:125-47. doi: 10.1007/978-1-60761-461-6_9.

PMID:
20379873
4.
5.

Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.

Meyer M, Hensbergen PJ, van der Raaij-Helmer EM, Brandacher G, Margreiter R, Heufler C, Koch F, Narumi S, Werner ER, Colvin R, Luster AD, Tensen CP, Werner-Felmayer G.

Eur J Immunol. 2001 Aug;31(8):2521-7.

6.

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P.

J Exp Med. 2003 Jun 2;197(11):1537-49.

7.

CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase.

Smit MJ, Verdijk P, van der Raaij-Helmer EM, Navis M, Hensbergen PJ, Leurs R, Tensen CP.

Blood. 2003 Sep 15;102(6):1959-65. Epub 2003 May 15.

8.

Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.

Basset L, Chevalier S, Danger Y, Arshad MI, Piquet-Pellorce C, Gascan H, Samson M.

J Mol Med (Berl). 2015 Dec;93(12):1355-67. doi: 10.1007/s00109-015-1319-6. Epub 2015 Jul 23.

PMID:
26199110
9.

CXCL10 contributes to p38-mediated apoptosis in primary T lymphocytes in vitro.

Sidahmed AM, León AJ, Bosinger SE, Banner D, Danesh A, Cameron MJ, Kelvin DJ.

Cytokine. 2012 Aug;59(2):433-41. doi: 10.1016/j.cyto.2012.05.002. Epub 2012 May 30.

10.

CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.

Berchiche YA, Sakmar TP.

Mol Pharmacol. 2016 Oct;90(4):483-95. doi: 10.1124/mol.116.105502. Epub 2016 Aug 10.

11.

CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.

Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, Lazzeri E, Angeli R, Rotondi M, Filì L, Parronchi P, Serio M, Maggi E, Romagnani S, Annunziato F.

J Allergy Clin Immunol. 2005 Dec;116(6):1372-9.

PMID:
16337473
12.

Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.

Cox JH, Dean RA, Roberts CR, Overall CM.

J Biol Chem. 2008 Jul 11;283(28):19389-99. doi: 10.1074/jbc.M800266200. Epub 2008 Apr 14.

13.

Evidence for PI3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells.

Willox I, Mirkina I, Westwick J, Ward SG.

Mol Immunol. 2010 Aug;47(14):2367-77. doi: 10.1016/j.molimm.2010.05.005. Epub 2010 Jun 2.

PMID:
20627397
14.

Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Jopling LA, Watt GF, Fisher S, Birch H, Coggon S, Christie MI.

Br J Pharmacol. 2007 Dec;152(8):1260-71. Epub 2007 Nov 5.

15.

Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Scholten DJ, Canals M, Wijtmans M, de Munnik S, Nguyen P, Verzijl D, de Esch IJ, Vischer HF, Smit MJ, Leurs R.

Br J Pharmacol. 2012 Jun;166(3):898-911. doi: 10.1111/j.1476-5381.2011.01648.x.

16.

Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.

Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG.

J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71. Epub 2005 Mar 10.

17.

CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).

Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD.

J Immunol. 2001 Dec 15;167(12):7084-93.

18.

CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.

Mueller A, Meiser A, McDonagh EM, Fox JM, Petit SJ, Xanthou G, Williams TJ, Pease JE.

J Leukoc Biol. 2008 Apr;83(4):875-82. doi: 10.1189/jlb.1006645. Epub 2008 Jan 3.

PMID:
18174362
19.

CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.

Giegold O, Ogrissek N, Richter C, Schröder M, Herrero San Juan M, Pfeilschifter JM, Radeke HH.

J Immunol. 2013 Apr 1;190(7):3696-705. doi: 10.4049/jimmunol.1101293. Epub 2013 Feb 27.

20.

Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.

Colvin RA, Campanella GS, Sun J, Luster AD.

J Biol Chem. 2004 Jul 16;279(29):30219-27. Epub 2004 May 17.

Supplemental Content

Support Center